Skip to content
10-K

Annual Report

Dianthus Therapeutics, Inc. DNTH

0001690585-26-000006

← back to feed
Filed
Mar 9, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 4, 2026 44.47M sh
Shares Diluted FY 2025 · Dec 31, 2025 38.62M sh
Shares Diluted FY 2025 · Dec 31, 2024 33.31M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$129.06M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$78.18M
Short Term Investments FY 2025 · Dec 31, 2025 $353.21M
Short Term Investments FY 2025 · Dec 31, 2024 $252.45M
Cash And Equivalents FY 2025 · Dec 31, 2025 $51.09M
Cash And Equivalents FY 2025 · Dec 31, 2024 $22.79M
Stockholders Equity FY 2025 · Dec 31, 2025 $493.4M
Stockholders Equity FY 2025 · Dec 31, 2024 $352.48M
Stockholders Equity FY 2025 · Dec 31, 2023 $168.87M
Current Liabilities FY 2025 · Dec 31, 2025 $30.73M
Current Liabilities FY 2025 · Dec 31, 2024 $18.45M
Total Liabilities FY 2025 · Dec 31, 2025 $37.52M
Total Liabilities FY 2025 · Dec 31, 2024 $21.53M
Current Assets FY 2025 · Dec 31, 2025 $409.44M
Current Assets FY 2025 · Dec 31, 2024 $280.9M
Total Assets FY 2025 · Dec 31, 2025 $530.92M
Total Assets FY 2025 · Dec 31, 2024 $374.01M
Eps Diluted FY 2025 · Dec 31, 2025 −$4.20
Eps Diluted FY 2025 · Dec 31, 2024 −$2.55
Eps Basic FY 2025 · Dec 31, 2025 −$4.20
Eps Basic FY 2025 · Dec 31, 2024 −$2.55
Sga Expense FY 2025 · Dec 31, 2025 $34.33M
Sga Expense FY 2025 · Dec 31, 2024 $24.99M
Rd Expense FY 2025 · Dec 31, 2025 $145.64M
Rd Expense FY 2025 · Dec 31, 2024 $83.11M
Net Income FY 2025 · Dec 31, 2025 −$162.34M
Net Income FY 2025 · Dec 31, 2024 −$84.97M
Operating Income FY 2025 · Dec 31, 2025 −$177.93M
Operating Income FY 2025 · Dec 31, 2024 −$101.86M
Revenue FY 2025 · Dec 31, 2025 $2.04M
Revenue FY 2025 · Dec 31, 2024 $6.24M